Terms: = Endocrine gland cancer AND FGFR4, CD334, 2264, ENSG00000160867, P22455, MGC20292, TKF, JTK2 AND Treatment
21 results:
1. Fibroblast Growth Factor Receptors and Ligands in Context of Bevacizumab Response in Ovarian Carcinoma: An Exploratory Analysis of AGO-OVAR11/ICON-7.
Heublein S; Pfisterer J; du Bois A; Anglesio M; Aminossadati B; Bhatti I; Sehouli J; Wimberger P; Schochter F; Hilpert F; Hillemanns P; Kalder M; Schroeder W; Mahner S; Burges A; Canzler U; Gropp-Meier M; Jackisch C; Harter P; Kommoss S; Marmé F
Lab Invest; 2024 Apr; 104(4):100321. PubMed ID: 38154497
[TBL] [Abstract] [Full Text] [Related]
2. Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma.
Afaq F; Agarwal S; Bajpai P; Diffalha SA; Kim HG; Peter S; Khushman M; Chauhan SC; Mukherjee P; Varambally S; Manne U
Neoplasia; 2024 Jan; 47():100951. PubMed ID: 38039923
[TBL] [Abstract] [Full Text] [Related]
3. Role of FGF Receptors and Their Pathways in Adrenocortical Tumors and Possible Therapeutic Implications.
Sbiera I; Kircher S; Altieri B; Lenz K; Hantel C; Fassnacht M; Sbiera S; Kroiss M
Front Endocrinol (Lausanne); 2021; 12():795116. PubMed ID: 34956100
[TBL] [Abstract] [Full Text] [Related]
4. Fibroblast growth factor receptor 4 (fgfr4) as detected by immunohistochemistry is associated with postoperative residual disease in ovarian cancer.
Heublein S; Anglesio MS; Marmé F; Kommoss S
J Cancer Res Clin Oncol; 2019 Sep; 145(9):2251-2259. PubMed ID: 31385026
[TBL] [Abstract] [Full Text] [Related]
5. treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).
Wirth LJ; Tahara M; Robinson B; Francis S; Brose MS; Habra MA; Newbold K; Kiyota N; Dutcus CE; Mathias E; Guo M; Sherman SI; Schlumberger M
Cancer; 2018 Jun; 124(11):2365-2372. PubMed ID: 29656442
[TBL] [Abstract] [Full Text] [Related]
6. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.
Ferrari SM; Bocci G; Di Desidero T; Elia G; Ruffilli I; Ragusa F; Orlandi P; Paparo SR; Patrizio A; Piaggi S; La Motta C; Ulisse S; Baldini E; Materazzi G; Miccoli P; Antonelli A; Fallahi P
Oncol Rep; 2018 May; 39(5):2225-2234. PubMed ID: 29517103
[TBL] [Abstract] [Full Text] [Related]
7. Lenvatinib in the Therapy of Aggressive Thyroid cancer: State of the Art and New Perspectives with Patents Recently Applied.
Ferrari SM; Ruffilli I; Centanni M; Virili C; Materazzi G; Alexopoulou M; Miccoli M; Antonelli A; Fallahi P
Recent Pat Anticancer Drug Discov; 2018; 13(2):201-208. PubMed ID: 29468981
[TBL] [Abstract] [Full Text] [Related]
8. cancer-associated fibroblasts secrete FGF-1 to promote ovarian proliferation, migration, and invasion through the activation of FGF-1/fgfr4 signaling.
Sun Y; Fan X; Zhang Q; Shi X; Xu G; Zou C
Tumour Biol; 2017 Jul; 39(7):1010428317712592. PubMed ID: 28718374
[TBL] [Abstract] [Full Text] [Related]
9. Anaplastic thyroid carcinoma and foscarnet use in a multitarget treatment documented by 18F-FDG PET/CT: A case report.
Giannetta E; Isidori AM; Durante C; Di Gioia C; Longo F; Tombolini V; Bulzonetti N; Graziadio C; Pofi R; Gianfrilli D; Verrienti A; Carletti R; Filetti S; Lenzi A; Baroli A
Medicine (Baltimore); 2017 Feb; 96(6):e5621. PubMed ID: 28178124
[TBL] [Abstract] [Full Text] [Related]
10. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.
Cabanillas ME; Schlumberger M; Jarzab B; Martins RG; Pacini F; Robinson B; McCaffrey JC; Shah MH; Bodenner DL; Topliss D; Andresen C; O'Brien JP; Ren M; Funahashi Y; Allison R; Elisei R; Newbold K; Licitra LF; Sherman SI; Ball DW
Cancer; 2015 Aug; 121(16):2749-56. PubMed ID: 25913680
[TBL] [Abstract] [Full Text] [Related]
11. Endoscopic endonasal transsphenoidal approach to large and giant pituitary adenomas: institutional experience and predictors of extent of resection.
Juraschka K; Khan OH; Godoy BL; Monsalves E; Kilian A; Krischek B; Ghare A; Vescan A; Gentili F; Zadeh G
J Neurosurg; 2014 Jul; 121(1):75-83. PubMed ID: 24785323
[TBL] [Abstract] [Full Text] [Related]
12. Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas.
Cassol CA; Winer D; Liu W; Guo M; Ezzat S; Asa SL
Mod Pathol; 2014 Aug; 27(8):1050-62. PubMed ID: 24390213
[TBL] [Abstract] [Full Text] [Related]
13. Identification of fgfr4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer.
Zaid TM; Yeung TL; Thompson MS; Leung CS; Harding T; Co NN; Schmandt RS; Kwan SY; Rodriguez-Aguay C; Lopez-Berestein G; Sood AK; Wong KK; Birrer MJ; Mok SC
Clin Cancer Res; 2013 Feb; 19(4):809-20. PubMed ID: 23344261
[TBL] [Abstract] [Full Text] [Related]
14. Ovarian metastasis and other ovarian neoplasms in women with cervical cancer stage IA-IIA.
Ngamcherttakul V; Ruengkhachorn I
Asian Pac J Cancer Prev; 2012; 13(9):4525-9. PubMed ID: 23167373
[TBL] [Abstract] [Full Text] [Related]
15. The fgfr4-G388R polymorphism promotes mitochondrial STAT3 serine phosphorylation to facilitate pituitary growth hormone cell tumorigenesis.
Tateno T; Asa SL; Zheng L; Mayr T; Ullrich A; Ezzat S
PLoS Genet; 2011 Dec; 7(12):e1002400. PubMed ID: 22174695
[TBL] [Abstract] [Full Text] [Related]
16. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Gelmon KA; Tischkowitz M; Mackay H; Swenerton K; Robidoux A; Tonkin K; Hirte H; Huntsman D; Clemons M; Gilks B; Yerushalmi R; Macpherson E; Carmichael J; Oza A
Lancet Oncol; 2011 Sep; 12(9):852-61. PubMed ID: 21862407
[TBL] [Abstract] [Full Text] [Related]
17. Targeting N-cadherin through fibroblast growth factor receptor-4: distinct pathogenetic and therapeutic implications.
Ezzat S; Zheng L; Winer D; Asa SL
Mol Endocrinol; 2006 Nov; 20(11):2965-75. PubMed ID: 16857743
[TBL] [Abstract] [Full Text] [Related]
18. Dual inhibition of RET and fgfr4 restrains medullary thyroid cancer cell growth.
Ezzat S; Huang P; Dackiw A; Asa SL
Clin Cancer Res; 2005 Feb; 11(3):1336-41. PubMed ID: 15709206
[TBL] [Abstract] [Full Text] [Related]
19. Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia.
Ezzat S; Zheng L; Asa SL
Mol Endocrinol; 2004 Oct; 18(10):2543-52. PubMed ID: 15231874
[TBL] [Abstract] [Full Text] [Related]
20. Growth hormone secretion elicited by GHRH, GHRP-6 or GHRH plus GHRP-6 in patients with microprolactinoma and macroprolactinoma before and after bromocriptine therapy.
Popovic V; Simic M; Ilic L; Micic D; Damjanovic S; Djurovic M; Obradovic S; Dieguez C; Casanueva F
Clin Endocrinol (Oxf); 1998 Jan; 48(1):103-8. PubMed ID: 9509075
[TBL] [Abstract] [Full Text] [Related]
[Next]